R&D channel feed – Endpoints News

R&D channel feed

Alnylam nears FDA filing for 4th RNAi therapy vutrisiran after late-stage data back use in protein misfolding disorder

5 years ago

Bristol Myers Squibb ices licensing pact with ArsenalBio to draft its designer T cells into the solid tumor fight

5 years ago

John Hood has found another misfit drug to love — and bring back from the dead

5 years ago

Imara attempts to spin weak data into an 'encouraging' result — but investors aren't having it

5 years ago

AbbVie eyes Humira matching move into psoriatic arthritis for immunology follow-up Skyrizi

5 years ago

BioXcel scores another win with reformulated Pfizer sedative, this time in an Alzheimer's symptom

5 years ago

In quick start to new year's M&A, Arvelle Therapeutics hands reins to Angelini as it nears EU approval for cenobamate

5 years ago

Slammed with PhII flop for lead drug, Calithera lays off a third of its staffers

5 years ago

The curious immunology behind the UK's surprise AstraZeneca dosing plan

5 years ago

Will they or won't they? The countdown on Bristol Myers' $6B CVR winds down to a hard deadline at the FDA

5 years ago

After a ‘breakthrough’ beginning to 2020, little Aprea gets crushed by a PhIII failure

5 years ago

Cytokinetics may walk a lonely road to market with tarnished heart med omecamtiv after last partner bows out

5 years ago

Supernus touts winning data in adult ADHD as it looks to make its case with the FDA — again — for pediatric use

5 years ago

After multiple setbacks, Bristol Myers scuttles Opdivo program for brain tumor patients after failing to prolong lives

5 years ago

Kiniksa whiffs on efficacy trying to repurpose an RA program for Covid-19, but spins survival 'trends' as a positive

5 years ago

Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many

5 years ago

A 'surprising' Phase III knocks back AstraZeneca, Amgen's blockbuster asthma ambitions

5 years ago

Following a quick approval in AML, Astellas' Xospata flops in chemo combo for frontline patients

5 years ago

Going head-to-head with Eylea, Roche touts PhIII win for bispecific blockbuster contender in diabetic macular edema

5 years ago

Novartis' biotech partner admits PhIII Covid-19 defeat for stem cell therapy, triggering extension of $1.2B+ deal close

5 years ago

In historic vote, mRNA vaccines go 2 and 0 as FDA experts unanimously back Moderna's Covid-19 vaccine

5 years ago

GlaxoSmithKline, Vir look to succeed where Lilly failed with NIH antibody study in hospitalized Covid-19 patients

5 years ago

Troubled AB Science claims breakout Alzheimer's success while vTv flops — again

5 years ago

Months into booming acute migraine launch, Biohaven chases prevention with oral CGRP med Nurtec ODT

5 years ago

First page Previous page 179 180 181182183 184 185 Next page Last page